Literature DB >> 13230993

Therapeutic results with chlorpromazine (largactil) in psychiatric conditions.

H E LEHMANN.   

Abstract

Entities:  

Keywords:  CHLORPROMAZINE/therapeutic use; MENTAL DISORDERS/therapy

Mesh：

Substances：

Year:  1955        PMID： 13230993      PMCID： PMC1825483     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN： 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  8 in total

1.  Effects of largactil in mental syndromes.

Authors:  H AZIMA; W OGLE
Journal:  Can Med Assoc J       Date:  1954-08       Impact factor: 8.262

2.  Chlorpromazine in the treatment of neuropsychiatric disorders.

Authors:  N W WINKELMAN
Journal:  J Am Med Assoc       Date:  1954-05-01

3.  [Technic of the hibernation therapy].

Authors:  G BREHMER; K T RUCKDESCHEL
Journal:  Dtsch Med Wochenschr       Date:  1953-12-11       Impact factor: 0.628

4.  [Preliminary report on artificial hibernation in the psychiatry].

Authors:  K KOLLE; M MIKOREY
Journal:  Dtsch Med Wochenschr       Date:  1953-12-11       Impact factor: 0.628

5.  New antiemetic drug; preliminary report.

Authors:  D G FRIEND; J F CUMMINS
Journal:  J Am Med Assoc       Date:  1953-10-03

6.  [Therapeutic method derived from hiberno-therapy in excitation and agitation states].

Authors:  J DELAY; P DENIKER; J M HARL
Journal:  Ann Med Psychol (Paris)       Date:  1952-07       Impact factor: 0.380

7.  Chlorpromazine; new inhibiting agent for psychomotor excitement and manic states.

Authors:  H E LEHMANN; G E HANRAHAN
Journal:  AMA Arch Neurol Psychiatry       Date:  1954-02

8.  [Artificial hibernation by pharmacodynamical and physical means].

Authors:  H LABORIT; P HUGUENARD
Journal:  Presse Med       Date:  1951-10-13       Impact factor: 1.228
  8 in total
  5 in total

1.  The response of chronically hospitalized, lobotomized patients to treatment with chlorpromazine and reserpine.

Authors:  A A KURLAND; T G WILLIAMS; T E HANLON
Journal:  Psychiatr Q       Date:  1959-10

2.  Studies on the cardiovascular actions of chlorpromazine. III. Effects on cerebral blood flow, blood pressure, and electrocorticogram, as recorded simultaneously.

Authors:  A ROMAGNOLI; K I MELVILLE
Journal:  Can Anaesth Soc J       Date:  1958-04

3.  Haemolytic anemia, jaundice and diabetes mellitus following chlorpromazine therapy.

Authors:  A A COOPERBERG; S EIDLOW
Journal:  Can Med Assoc J       Date:  1956-11-01       Impact factor: 8.262

4.  Seizures occurring during intensive chlorpromazine therapy.

Authors:  W SCHLICHTHER; M E BRISTOW; S SCHULTZ; A L HENDERSON
Journal:  Can Med Assoc J       Date:  1956-03-01       Impact factor: 8.262

5.  Who pioneered the use of antipsychotics in North America?

Authors:  Emmanuel Stip
Journal:  Can J Psychiatry       Date:  2015-03       Impact factor: 4.356
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.